jason
1.9K posts


I've just published ~2 million MT1 and MT2 peptide analogs as §102 prior art with full pharmacology and synthesis protocols. This is clearcutting any future patents of this class of peptide. I chose MT1+2 as a demonstration because they are the least likely to be monetized, and the least useful. The reason for this is credibility, so there is little doubt when I say that I have about 98% of the patentable peptide analogs, all as high fidelity as the ones I just published, all with grade A markush filtering. In total it's about 140 million analogs across 87 classes. I've predicted about 600 of those to be S+ tier in terms of effectiveness, etc. Ozempic without the osteoporosis, things like this. I am not planning to publish any more analogs as prior art, but I could clearcut the entire peptide IP field. I think that would be foolish, so this catalog is available to purchase through inquiry on the coracle research website. I will only give this information to one buyer, biggest number wins, good luck! coracleresearch.com/research/07-me…







"we need privacy on the blockchain" brothers we already have this and it works splendidly


ALARMING🚨: Tiny plastic fragments have now been directly visualized inside the human brain.




@orbs_exe you're never nobody when you put on the milady, milady



Angels can be found in strange places





Milady is the only NFT that will not benefit from the coming Ape Supercycle.














